Dornase alfa
| Clinical data | |
|---|---|
| Trade names | Pulmozyme |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a694002 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Inhalation |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.029.685 |
| Chemical and physical data | |
| Formula | C1321H1999N339O396S9 |
| Molar mass | 29254.04 g·mol−1 |
| (what is this?) (verify) | |
Dornase alfa, sold under the brand name Pulmozyme, is used for the treatment of cystic fibrosis. It is a recombinant human deoxyribonuclease I (rhDNase), an enzyme which selectively cleaves DNA. Dornase alfa hydrolyzes the DNA present in sputum/mucus and reduces viscosity in the lungs, promoting improved clearance of secretions. It is produced in Chinese hamster ovary cells.